Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.

IF 1.3 Q4 ENDOCRINOLOGY & METABOLISM

Diabetology International Pub Date : 2023-06-15 eCollection Date: 2023-10-01 DOI:10.1007/s13340-023-00638-w

Yukiko Onishi, Shinichiro Shirabe, Kosei Eguchi, Keiji Nishijima, Toshihiro Sato, Hiroaki Seino

{"title":"Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.","authors":"Yukiko Onishi, Shinichiro Shirabe, Kosei Eguchi, Keiji Nishijima, Toshihiro Sato, Hiroaki Seino","doi":"10.1007/s13340-023-00638-w","DOIUrl":null,"url":null,"abstract":"Introduction: The CAPTURE study estimated the global prevalence of established cardiovascular disease (CVD) and characterized the usage of glucose-lowering agents (GLAs) in adults with type 2 diabetes (T2D) across 13 countries. The purpose of this secondary analysis of data from the Japanese sites within CAPTURE (NCT03786406, NCT03811288) was to provide data about medication usage stratified by CVD status among Japanese participants with T2D.Materials and methods: Data on GLA usage (including those with proven cardiovascular [CV] benefits) in Japanese participants with T2D managed in clinics or hospitals were collected and stratified by CVD subgroups.Results: There were 800 Japanese participants in the CAPTURE study (n = 502 [no CVD group], n = 298 [CVD group], n = 268 [atherosclerotic CVD subgroup]). Oral antidiabetic agents and insulin were used by 88.5% and 23.4%, respectively, of participants overall. Among participants with established CVD, dipeptidyl peptidase-4 inhibitors (65.1%) were most frequently used, followed by biguanides (50.7%) and insulins (26.2%). The pattern was similar among participants with atherosclerotic CVD. A lower proportion of participants in the CVD group used glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) with proven CV benefits versus the no CVD group (GLP-1 RAs: 7.0% vs. 8.6%; SGLT-2is: 13.4% vs. 19.1%).Conclusion: This analysis of the CAPTURE study provided a comprehensive overview of prescription patterns for the treatment of T2D in Japan. Use of GLAs with proven CV benefit was low, even in participants with established CVD, which was comparable to the findings from the global cohort.Supplementary information: The online version contains supplementary material available at 10.1007/s13340-023-00638-w.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533472/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13340-023-00638-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The CAPTURE study estimated the global prevalence of established cardiovascular disease (CVD) and characterized the usage of glucose-lowering agents (GLAs) in adults with type 2 diabetes (T2D) across 13 countries. The purpose of this secondary analysis of data from the Japanese sites within CAPTURE (NCT03786406, NCT03811288) was to provide data about medication usage stratified by CVD status among Japanese participants with T2D.

Materials and methods: Data on GLA usage (including those with proven cardiovascular [CV] benefits) in Japanese participants with T2D managed in clinics or hospitals were collected and stratified by CVD subgroups.

Results: There were 800 Japanese participants in the CAPTURE study (n = 502 [no CVD group], n = 298 [CVD group], n = 268 [atherosclerotic CVD subgroup]). Oral antidiabetic agents and insulin were used by 88.5% and 23.4%, respectively, of participants overall. Among participants with established CVD, dipeptidyl peptidase-4 inhibitors (65.1%) were most frequently used, followed by biguanides (50.7%) and insulins (26.2%). The pattern was similar among participants with atherosclerotic CVD. A lower proportion of participants in the CVD group used glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) with proven CV benefits versus the no CVD group (GLP-1 RAs: 7.0% vs. 8.6%; SGLT-2is: 13.4% vs. 19.1%).

Conclusion: This analysis of the CAPTURE study provided a comprehensive overview of prescription patterns for the treatment of T2D in Japan. Use of GLAs with proven CV benefit was low, even in participants with established CVD, which was comparable to the findings from the global cohort.

Supplementary information: The online version contains supplementary material available at 10.1007/s13340-023-00638-w.

查看原文本刊更多论文

日本成人T2D和CVD患者糖尿病药物的使用：CAPTURE研究的二次分析。

引言：CAPTURE研究估计了全球心血管疾病（CVD）的患病率，并描述了13个国家成人2型糖尿病（T2D）患者使用降血糖剂的情况。对CAPTURE（NCT03786406，NCT03811288）内日本站点的数据进行二次分析的目的是提供日本T2D参与者中按CVD状态分层的药物使用数据。材料和方法：收集在诊所或医院管理的日本T2D患者的GLA使用数据（包括经证实具有心血管[CV]益处的数据）并按CVD亚组进行分层。结果：共有800名日本人参与了CAPTURE研究（n = 502[无CVD组]，n = 298[CVD组]，n = 268[动脉粥样硬化性CVD亚组]）。总体而言，88.5%和23.4%的参与者分别使用了口服抗糖尿病药物和胰岛素。在已确诊的心血管疾病参与者中，二肽基肽酶-4抑制剂（65.1%）最常使用，其次是双胍类（50.7%）和胰岛素类（26.2%）。动脉粥样硬化性心血管疾病参与者的使用模式相似。与无CVD组相比，CVD组中使用胰高血糖素样肽-1受体激动剂（GLP-1 RAs）和钠-葡萄糖协同转运蛋白-2抑制剂（SGLT-2is）的参与者比例较低（GLP-1 RAs:7.0%vs.8.6%；SGLT-2is:113.4%vs.19.1%）T2D在日本。即使在患有心血管疾病的参与者中，使用经证实具有心血管疾病益处的GLAs的情况也很低，这与全球队列的研究结果相当。补充信息：在线版本包含补充材料，网址为10.1007/s13340-023-00638-w。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetology International ENDOCRINOLOGY & METABOLISM-

CiteScore

3.90

自引率

4.50%

发文量

期刊介绍： Diabetology International, the official journal of the Japan Diabetes Society, publishes original research articles about experimental research and clinical studies in diabetes and related areas. The journal also presents editorials, reviews, commentaries, reports of expert committees, and case reports on any aspect of diabetes. Diabetology International welcomes submissions from researchers, clinicians, and health professionals throughout the world who are interested in research, treatment, and care of patients with diabetes. All manuscripts are peer-reviewed to assure that high-quality information in the field of diabetes is made available to readers. Manuscripts are reviewed with due respect for the author''s confidentiality. At the same time, reviewers also have rights to confidentiality, which are respected by the editors. The journal follows a single-blind review procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Single-blind peer review is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.